Addition of Icosapent Ethyl Cuts CV Risk in Patients With Prior PCI
THURSDAY, March 24, 2022 -- The risk for cardiovascular events is reduced in statin-treated patients with elevated triglycerides and a history of percutaneous coronary intervention (PCI) who receive icosapent ethyl, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Angioplasty | Cardiology | Cardiovascular | Cholesterol | Coronary Angioplasty | Heart | Percutaneous Coronary Intervention | Pharmaceuticals | Statin Therapy | Study